Q4 Earnings Forecast for Altimmune Issued By B. Riley

Altimmune, Inc. (NASDAQ:ALT) – Analysts at B. Riley issued their Q4 2026 earnings per share (EPS) estimates for Altimmune in a note issued to investors on Thursday, November 6th. B. Riley analyst M. Mamtani expects that the company will earn ($0.31) per share for the quarter. B. Riley currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%.

ALT has been the subject of several other research reports. UBS Group cut their price target on Altimmune from $26.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Wall Street Zen raised Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Wednesday, October 8th. Finally, Citizens Jmp reduced their price objective on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $16.83.

Altimmune Stock Up 0.5%

NASDAQ ALT opened at $4.28 on Monday. Altimmune has a twelve month low of $2.90 and a twelve month high of $11.16. The stock has a market cap of $377.74 million, a PE ratio of -3.63 and a beta of 0.01. The firm has a 50-day simple moving average of $3.89 and a 200 day simple moving average of $4.52. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its holdings in shares of Altimmune by 108.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after purchasing an additional 5,253 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new position in Altimmune in the second quarter valued at about $40,000. Prudential Financial Inc. acquired a new position in Altimmune in the second quarter valued at about $43,000. Sequoia Financial Advisors LLC bought a new stake in Altimmune during the third quarter worth about $46,000. Finally, Headland Capital LLC acquired a new stake in shares of Altimmune during the first quarter worth approximately $50,000. 78.05% of the stock is owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.